CA3250301A1 - COMBINATION OF CYTOKINE FUSION PROTEINS WITH CD8 ANTIGEN-BINDING MOLECULES - Google Patents

COMBINATION OF CYTOKINE FUSION PROTEINS WITH CD8 ANTIGEN-BINDING MOLECULES

Info

Publication number
CA3250301A1
CA3250301A1 CA3250301A CA3250301A CA3250301A1 CA 3250301 A1 CA3250301 A1 CA 3250301A1 CA 3250301 A CA3250301 A CA 3250301A CA 3250301 A CA3250301 A CA 3250301A CA 3250301 A1 CA3250301 A1 CA 3250301A1
Authority
CA
Canada
Prior art keywords
combination
antigen binding
fusion proteins
binding molecules
cytokine fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3250301A
Other languages
English (en)
French (fr)
Inventor
Ivana DJURETIC
Renee L. Greer
Yik Andy Yeung
Original Assignee
Asher Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asher Biotherapeutics Inc filed Critical Asher Biotherapeutics Inc
Publication of CA3250301A1 publication Critical patent/CA3250301A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3250301A 2022-04-27 2023-04-26 COMBINATION OF CYTOKINE FUSION PROTEINS WITH CD8 ANTIGEN-BINDING MOLECULES Pending CA3250301A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263335697P 2022-04-27 2022-04-27
US63/335,697 2022-04-27
PCT/US2023/019989 WO2023212056A2 (en) 2022-04-27 2023-04-26 Combination of cytokine fusion proteins with cd8 antigen binding molecules

Publications (1)

Publication Number Publication Date
CA3250301A1 true CA3250301A1 (en) 2023-11-02

Family

ID=88519563

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3250301A Pending CA3250301A1 (en) 2022-04-27 2023-04-26 COMBINATION OF CYTOKINE FUSION PROTEINS WITH CD8 ANTIGEN-BINDING MOLECULES

Country Status (9)

Country Link
US (1) US20250339519A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514397A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025515470A (cg-RX-API-DMAC7.html)
KR (1) KR20250027597A (cg-RX-API-DMAC7.html)
CN (1) CN119546343A (cg-RX-API-DMAC7.html)
AU (1) AU2023259161A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250301A1 (cg-RX-API-DMAC7.html)
TW (1) TW202400664A (cg-RX-API-DMAC7.html)
WO (1) WO2023212056A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
WO2026162740A1 (en) * 2025-01-31 2026-08-06 Astrazeneca Ab Cd8-binding cytokine engager combination therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200306301A1 (en) * 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
JP2020533971A (ja) * 2017-08-28 2020-11-26 アルター・バイオサイエンス・コーポレーション Il−15をベースとするil−7及びil−21への融合物
JP7778571B2 (ja) * 2019-06-05 2025-12-02 アッシャー バイオセラピューティクス, インコーポレイテッド 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体
EP4175979A2 (en) * 2020-07-02 2023-05-10 Inhibrx, Inc. Polypeptides comprising modified il-2 polypeptides and uses thereof
KR20230086765A (ko) * 2020-10-13 2023-06-15 얀센 바이오테크 인코포레이티드 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
KR20230112632A (ko) * 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
WO2022245500A1 (en) * 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs

Also Published As

Publication number Publication date
JP2025515470A (ja) 2025-05-15
KR20250027597A (ko) 2025-02-26
EP4514397A2 (en) 2025-03-05
AU2023259161A1 (en) 2024-11-28
TW202400664A (zh) 2024-01-01
WO2023212056A2 (en) 2023-11-02
US20250339519A1 (en) 2025-11-06
WO2023212056A3 (en) 2023-12-07
EP4514397A4 (en) 2026-05-20
CN119546343A (zh) 2025-02-28

Similar Documents

Publication Publication Date Title
DK3972987T5 (da) Antigenspecifik immunterapi til COVID-19-fusionsproteiner og fremgangsmåder til anvendelse deraf
EP4232071A4 (en) FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
AU2022242125A1 (en) Proteins comprising cd3 antigen binding domains and uses thereof
AU2021403658A9 (en) Recombinant cd3 binding proteins and their use
EP4126965A4 (en) ANTI-PD-L1 ANTIBODIES AND ANTI-PD-L1/IL10 FUSION PROTEINS
EP4168124A4 (en) ANTI-PD-1 ANTIBODIES AND FUSION PROTEINS
EP4274614A4 (en) ANTI-PD-L1 ANTIBODIES AND CORRESPONDING FUSION PROTEINS
AU2024265777A1 (en) Methods of using il-18 fusion proteins
HK40123367A (en) Combination of cytokine fusion proteins with cd8 antigen binding molecules
EP3983450A4 (en) ANTI-PD-L1/ANTI-LAG-3 PROTEINS WITH MULTIPLE ANTIGEN BINDING AND METHODS FOR THEIR USE
WO2023212056A3 (en) Combination of cytokine fusion proteins with cd8 antigen binding molecules
AU2024334289A1 (en) Anti-il-13 multispecific antibody constructs and uses thereof
EP4286520A4 (en) Antigen-binding protein and use thereof
EP4330277A4 (en) Multimerization of binding molecules with a variant of the constant region of an antibody
CA3301507A1 (en) Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
CA3265178A1 (en) Antigen-binding proteins and their uses
CA3283890A1 (en) Multispecific antigen binding proteins and uses thereof
HK40103094A (en) Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function
CA3284529A1 (en) Antigen binding molecules and methods of use
HK40113395A (en) Antigen binding proteins and uses thereof
HK40093081A (en) Recombinant cd3 binding proteins and their use
HK40103847A (en) Anti-ctla-4 binding proteins and methods of use thereof
CA3292582A1 (en) Antibodies targeting xcl1 and methods of using the same
HK40084390A (en) Anti-ctla-4 binding proteins and methods of use thereof
AU2023903973A0 (en) Binding proteins and methods and uses thereof

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241022

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241204

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241205

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250106